BR0011696A - Composições e métodos para aumento do efluxo de colesterol e elevação de hdl usando proteìna abc1 transportadora de cassete de ligação de atp - Google Patents

Composições e métodos para aumento do efluxo de colesterol e elevação de hdl usando proteìna abc1 transportadora de cassete de ligação de atp

Info

Publication number
BR0011696A
BR0011696A BR0011696-3A BR0011696A BR0011696A BR 0011696 A BR0011696 A BR 0011696A BR 0011696 A BR0011696 A BR 0011696A BR 0011696 A BR0011696 A BR 0011696A
Authority
BR
Brazil
Prior art keywords
abc1
methods
compositions
cholesterol efflux
increasing
Prior art date
Application number
BR0011696-3A
Other languages
English (en)
Inventor
Richard M Lawn
David Wade
Michael Garvin
John F Oram
Original Assignee
Cv Therapeutics Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc, Univ Washington filed Critical Cv Therapeutics Inc
Publication of BR0011696A publication Critical patent/BR0011696A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA AUMENTO DO EFLUXO DE COLESTEROL E ELEVAçãO DE HDL USANDO PROTEìNA ABC1 TRANSPORTADORA DE CASSETE DE LIGAçãO DE ATP". A presente invenção está relacionada a novos polipeptídeos de ABC1 e moléculas de ácido nucleico que codificam o mesmo. A invenção também está relacionada a vetores recombinantes, células hospedeiras, e composições que compreendem polinucleotídeos de ABC1, assim como a métodos para produção dé polipeptídeos de ABC1. A invenção também está relacionada a anticorpos que se ligam especificamente a polipeptídeos de ABC1. Em adição, a invenção está relacionada a métodos para aumentar o efluxo de colesterol assim como a métodos para aumentar a expressão e atividade de ABC1. A presente invenção também está relacionada a métodos para identificar compostos que modulam a expressão de ABC1 e métodos para detectar o nível comparativo de polipeptídeos e polinucleotídeos de ABC1 em um indivíduo mamífero. A presente invenção também fornece kits e composições adequados para escolha de compostos para determinar a atividade moduladora do composto para expressão de ABC1, assim como kits e composições adequados para determinar se um composto modula o efluxo de colesterol dependente de ABC1.
BR0011696-3A 1999-06-18 2000-06-16 Composições e métodos para aumento do efluxo de colesterol e elevação de hdl usando proteìna abc1 transportadora de cassete de ligação de atp BR0011696A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14026499P 1999-06-18 1999-06-18
US15387299P 1999-09-14 1999-09-14
US16657399P 1999-11-19 1999-11-19
PCT/US2000/016591 WO2000078971A2 (en) 1999-06-18 2000-06-16 Atp binding cassette transporter protein abc1 popypeptides

Publications (1)

Publication Number Publication Date
BR0011696A true BR0011696A (pt) 2002-04-30

Family

ID=27385472

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0011753-6A BR0011753A (pt) 1999-06-18 2000-06-16 Composições e métodos para aumentar o efluxo de colesterol e elevar o hdl utilizando a proteìna abc1 transportadora do cassete de ligação de atp
BR0011696-3A BR0011696A (pt) 1999-06-18 2000-06-16 Composições e métodos para aumento do efluxo de colesterol e elevação de hdl usando proteìna abc1 transportadora de cassete de ligação de atp

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0011753-6A BR0011753A (pt) 1999-06-18 2000-06-16 Composições e métodos para aumentar o efluxo de colesterol e elevar o hdl utilizando a proteìna abc1 transportadora do cassete de ligação de atp

Country Status (19)

Country Link
EP (2) EP1190065A2 (pt)
JP (4) JP2003508031A (pt)
KR (2) KR100476519B1 (pt)
CN (2) CN1379817A (pt)
AR (2) AR024576A1 (pt)
AT (1) ATE422545T1 (pt)
AU (3) AU777461B2 (pt)
BR (2) BR0011753A (pt)
CA (2) CA2375787C (pt)
DE (1) DE60041545D1 (pt)
HK (2) HK1046427A1 (pt)
IL (2) IL147021A0 (pt)
MX (2) MXPA01013174A (pt)
NO (2) NO20016114L (pt)
NZ (3) NZ531401A (pt)
SG (2) SG121852A1 (pt)
TR (2) TR200200441T2 (pt)
TW (2) TWI304737B (pt)
WO (2) WO2000078972A2 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1100895T1 (de) 1999-03-15 2001-09-06 The University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
EP1854880A1 (en) * 1999-03-15 2007-11-14 University of British Columbia Methods and reagents for modulating cholesterol levels
AU6074700A (en) * 1999-07-08 2001-01-30 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
WO2001015676A2 (en) * 1999-09-01 2001-03-08 University Of British Columbia Compositions and methods for modulating hdl cholesterol and triglyceride levels
US6555323B2 (en) * 2000-02-08 2003-04-29 Pfizer Inc. Assay for ABCA1
NZ522360A (en) 2000-05-02 2004-12-24 Aventis Pharma Sa Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses
EP1203588A1 (en) * 2000-11-06 2002-05-08 Bayer Ag Sterol-independent regulation of ABC1 promoter via oncostatinM
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
AU2002317093A1 (en) * 2001-07-03 2003-01-21 University Of British Columbia Screening processes for agents modulating cholesterol levels
CA2463395A1 (en) * 2001-10-12 2003-04-24 Grelan Pharmaceutical Co., Ltd. Therapeutic agents for low hdl-cholesterolemia
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
US6696473B2 (en) 2001-12-21 2004-02-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
ATE496893T1 (de) 2002-12-20 2011-02-15 X Ceptor Therapeutics Inc Isochinolinonderivate und deren verwendung als medikamente
RU2006105646A (ru) 2003-07-23 2007-09-10 Экселиксис, Инк. (Us) Производные азепина в качестве фармацевтических агентов
WO2005116057A1 (en) * 2004-05-27 2005-12-08 Baker Medical Research Institute Monoclonal antibody against abca1
EP2172484A3 (en) 2005-05-18 2010-05-19 Ablynx N.V. Serum albumin binding proteins
CN101213214B (zh) 2005-05-20 2014-06-25 埃博灵克斯股份有限公司 针对冯威勒布兰特因子的单一结构域vhh抗体
AU2006261845C1 (en) 2005-06-27 2013-05-16 Exelixis Patent Company Llc Imidazole based LXR modulators
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
WO2008062830A1 (fr) 2006-11-24 2008-05-29 Hykes Laboratories Llc Composé de spiroquinone et composition pharmaceutique
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
US20100062004A1 (en) 2006-12-19 2010-03-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
WO2009068625A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
GB2470328A (en) 2008-03-05 2010-11-17 Ablynx Nv Novel antigen binding dimer complexes, methods of making and uses thereof
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
ES2610622T3 (es) * 2009-03-31 2017-04-28 The General Hospital Corporation Regulación de microARN miR-33 en el tratamiento de trastornos relacionados con colesterol
BRPI1013877A2 (pt) 2009-04-10 2017-08-15 Ablynx Nv Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
CA2761934C (en) 2009-05-28 2018-01-09 Exelixis Patent Company Llc Substituted 1-(biphenyl-4-yl)-2-benzyl-4-hydroxyalkyl-1h-imidazole compounds and their use as lxr modulators
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
EA037063B1 (ru) 2010-11-08 2021-02-01 Аблинкс Н.В. Cxcr2-связывающие полипептиды
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2013188740A1 (en) 2012-06-14 2013-12-19 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
US9101745B2 (en) * 2013-03-14 2015-08-11 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor
US9834542B2 (en) 2013-03-15 2017-12-05 Bristo-Myers Squibb Company LXR modulators
JP6456909B2 (ja) 2013-03-15 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
GB201315136D0 (en) * 2013-08-23 2013-10-09 Univ Glasgow Cholesterol modulation
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
AU2016360987A1 (en) 2015-11-27 2018-06-07 Ablynx Nv Polypeptides inhibiting CD40L
EP3512880A1 (en) 2016-09-15 2019-07-24 Ablynx NV Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
US11840569B2 (en) 2016-11-16 2023-12-12 Ablynx N.V. T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
MX2019014504A (es) 2017-06-02 2020-07-20 Merck Patent Gmbh Inmunoglobulinas de union a agrecano.
TWI825021B (zh) 2017-06-02 2023-12-11 德商麥克專利有限公司 與ｍｍｐ１３結合之免疫球蛋白
TWI802576B (zh) 2017-06-02 2023-05-21 德商馬克專利公司 與ａｄａｍｔｓ結合之免疫球蛋白
TW202428621A (zh) 2017-06-02 2024-07-16 德商麥克專利有限公司 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
CN115433733A (zh) 2021-06-04 2022-12-06 生物岛实验室 环状RNA Circ-ACE2翻译的多肽及其应用
CN114369162B (zh) 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
WO2024023271A1 (en) 2022-07-27 2024-02-01 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522360A (en) * 2000-05-02 2004-12-24 Aventis Pharma Sa Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses

Also Published As

Publication number Publication date
IL147022A0 (en) 2002-08-14
EP1218515B1 (en) 2009-02-11
CA2375787A1 (en) 2000-12-28
CN1434865A (zh) 2003-08-06
AR024576A1 (es) 2002-10-16
CN1379817A (zh) 2002-11-13
WO2000078972A3 (en) 2002-05-02
NO20016114D0 (no) 2001-12-14
TWI259205B (en) 2006-08-01
HK1046708A1 (zh) 2003-01-24
CA2375787C (en) 2007-03-27
TW200626176A (en) 2006-08-01
AR024391A1 (es) 2002-10-02
SG121852A1 (en) 2006-05-26
TWI304737B (en) 2009-01-01
TR200200441T2 (tr) 2002-11-21
MXPA01013175A (es) 2002-06-04
NZ531401A (en) 2005-08-26
NZ516061A (en) 2004-04-30
ATE422545T1 (de) 2009-02-15
WO2000078971A2 (en) 2000-12-28
IL147021A0 (en) 2002-08-14
NO20016114L (no) 2002-02-12
AU2005200171A1 (en) 2005-02-10
JP2003506097A (ja) 2003-02-18
JP2005112859A (ja) 2005-04-28
DE60041545D1 (de) 2009-03-26
WO2000078972A9 (en) 2002-07-18
AU5743400A (en) 2001-01-09
KR20020012281A (ko) 2002-02-15
NO20016121D0 (no) 2001-12-14
EP1218515A2 (en) 2002-07-03
JP2003508031A (ja) 2003-03-04
EP1190065A2 (en) 2002-03-27
HK1046427A1 (zh) 2003-01-10
TR200200440T2 (tr) 2002-09-23
KR20020012612A (ko) 2002-02-16
CN100513570C (zh) 2009-07-15
AU5746700A (en) 2001-01-09
WO2000078972A2 (en) 2000-12-28
BR0011753A (pt) 2002-04-30
SG121853A1 (en) 2006-05-26
KR100476519B1 (ko) 2005-03-17
JP2006137750A (ja) 2006-06-01
MXPA01013174A (es) 2002-06-04
WO2000078971A3 (en) 2002-01-17
JP4277956B2 (ja) 2009-06-10
NZ529785A (en) 2005-09-30
AU777461B2 (en) 2004-10-14
NO20016121L (no) 2002-02-12
WO2000078972A8 (en) 2001-06-21
CA2375781A1 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
BR0011696A (pt) Composições e métodos para aumento do efluxo de colesterol e elevação de hdl usando proteìna abc1 transportadora de cassete de ligação de atp
Meyer et al. Orthogonal protein decoration of DNA nanostructures
Saccà et al. Orthogonal protein decoration of DNA origami
CA2341636A1 (en) Fusion proteins, dna molecules, vectors, and host cells useful for measuring protease activity
Sebastiano et al. A new deuterated alkylating agent for quantitative proteomics
CA2449201A1 (en) Acridone derivatives as labels for fluorescence detection of target materials
Yanagisawa et al. A matrix attachment region (MAR)-binding activity due to a p114 kilodalton protein is found only in human breast carcinomas and not in normal and benign breast disease tissues
CA2449409A1 (en) Quinacridone labelling reagents for fluorescence detection of biological materials
ATE316573T1 (de) Wechselwirkendes fallensystem zur isolierung von proteinen
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
CA2324379A1 (en) Anthrax lethal factor is a mapk kinase protease
Cai et al. Peptoid ligands that bind selectively to phosphoproteins
Moore et al. Proliferating cell nuclear antigen/cyclin is an interleukin 2-responsive gene.
ATE350472T1 (de) Jmy, mit-aktivator für p300/cbp, dafür kodierendenucleinsäure und deren verwendungen
Schwanbeck et al. Cdc2 and Mitogen-activated Protein Kinases Modulate DNA Binding Properties of the Putative Transcriptional RegulatorChironomus High Mobility Group Protein I
ATE224953T1 (de) Paraoxonase aus serum
BR0313151A (pt) métodos e reagentes que se relacionam à inflamação e à apoptose
Rübsamen et al. Identification of a calcium-binding subunit of the acetylcholine receptor
EP0997476A3 (en) Antibodies to a mammalian Langerhans cell antigen and their uses
Linsley et al. Affinity labeling of hormone receptors and other ligand binding proteins
Mendelson et al. Mapping the binding of monoclonal antibodies to histone H5
EP0289187A3 (en) Vinyl substituted radiohalogen conjugates for protein labeling
ATE110469T1 (de) Nichttrennender festphasen-enzymtest.
WO2002087606A3 (en) Modulators of the hypocretin system and methods of screening therefor
Nakamura Two types of proton-modulated calcium binding in the sarcoplasmic reticulum Ca (2+)-ATPase. II. Characteristics of their calcium bindings.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O, 8O E 9O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.